Spinraza nusinersen

Procedure burden at scoliosis-fused spines is the single biggest adherence leak and the primary driver of switches to Evrysdi, making injection-experience peer support the highest-ROI patient-services intervention available.

• Lumbar puncture complexity in adults with spinal fusions is the top lived-experience barrier, producing anxiety, multi-attempt procedures, and post-injection nerve pain that directly drives discontinuation within two years for more than half of starters.
• Patients report a distinct 'Spinraza slump' of worsening strength in the weeks before each maintenance dose, a cycle-dependent adherence risk that is largely invisible to clinical teams but highly salient in peer communities.
• Access and insurance navigation (Medicare buy-and-bill complexity, prior authorization, six-figure per-dose hospital billing) consumes enormous caregiver and patient energy before the first dose is even administered.
• The newly approved high-dose regimen and a decade of safety data are generating renewed community optimism, creating a re-engagement window for patients who previously discontinued or plateaued on the standard 12 mg dose.